Symbols

ALLR

Allarity·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

Low Cash Short-term Debt Ratio

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ALLR

Allarity Therapeutics, Inc.

A clinical-stage biopharmaceutical company engages in developing oncology therapeutics

Industry

Pharmaceutical

Established Date

04/06/2021

Listing Date

12/21/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.allarity.com

Security Type

Common stock

Office address

123 E. Tarpon Ave. Tarpon Springs FL 34689

Business

Introduction

Allarity Therapeutics, Inc., was incorporated in Delaware on April 6, 2021. The company is a clinical-stage precision medicine pharmaceutical company focused on developing anticancer therapies using its drug response prediction platform. Its lead drug candidate, stenoparib, is a dual PARP/tankyrase inhibitor being developed for platinum-resistant ovarian cancer and small cell lung cancer, along with companion diagnostic reagents to identify patients who may benefit.

Company Financials

EPS

ALLR has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.21, beating expectations. The chart below visualizes how ALLR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ALLR has released its 2025 Q4 earnings report, with revenue of 320.00K, reflecting a YoY change of NaN%, and net profit of -3.37M, showing a YoY change of 54.74%. The Sankey diagram below clearly presents ALLR's revenue sources and cost distribution.